FAQ on New Therapeutic Developments in Relapsed/Refractory Multiple Myeloma

In this episode, Jesús F. San-Miguel, MD, PhD; Paula Rodriguez-Otero, MD, PhD; and  Prof. Dr. med. Katja Weisel answer questions focused on current and emerging therapies for early and late relapsed, refractory multiple myeloma, with topics including:

• Responses across different subgroups treated with idecabtagene vicleucel in the KarMMa trial 

• Selecting therapy for a patient with lenalidomide-refractory disease at first relapse

• How CAR T-cell therapy, melflufen, and selinexor will fit into existing and future treatment algorithms

• Key findings from the DREAMM2 trial on belantamab mafodotin

• Monitoring and management strategies for ocular toxicity with belantamab mafodotin

Presenters:

Jesús F. San-Miguel, MD, PhD
Director of Clinical and Translational Medicine
Universidad de Navarra
Pamplona, Spain

Paula Rodriguez-Otero, MD, PhD
Associate Professor
Consultant in Hematology
Department of Hematology, Clínica Universidad de Navarra
University of Navarra
Pamplona, Spain

Prof. Dr. med. Katja Weisel  
Deputy Director
II. Medical Clinic and Polyclinic
Department of Oncology and Hematology
Department of Pneumology and Bone Marrow Transplantation
University Medical Center  
Hamburg-Eppendorf
Hamburg, Germany

Content based on an online CME program supported by an educational grant from GlaxoSmithKline.

Link to full program, including associated downloadable slidesets: 

https://bit.ly/2QRqYuC

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.